Amycretin Is Basically CagriSema in One Molecule. Here’s Why the Phase 2 Diabetes Data Matters
Novo Nordisk just showed that a single weekly amycretin injection pulled average HbA1c down 1.8 points and shaved 14.5% of body weight in 36 weeks for people whose diabetes meds had stopped working. That is almost the same metabolic punch CagriSema delivered with two actives in one pen. The twist? Amycretin also has an oral version that hit 10.1% weight loss in the same timeframe. Combine those two facts and you start to see why Novo abruptly greenlit a full Phase 3 diabetes program for what used to be an obesity-first candidate.
If you are navigating type 2 diabetes on metformin plus an SGLT2 inhibitor, this data should have your attention. Most GLP-1 drugs force you to choose between injectable potency and oral convenience. Amycretin looks ready to blur that line.
What amycretin actually is
Amycretin is a single peptide that mimics both GLP-1 and amylin signaling. GLP-1 slows gastric emptying, increases insulin release, and suppresses glucagon after meals. Amylin, which healthy pancreases secrete alongside insulin, blunts post-meal glucose spikes and sends satiety signals to the brain. Novo already married those two effects in CagriSema by mixing semaglutide with a long-acting amylin analog. Amycretin takes the same concept but folds it into one peptide sequence so you do not need to co-formulate two separate actives.
Why does that matter? Manufacturing capacity. Novo can produce one peptide at scale instead of two, fill a single cartridge, and keep the cold chain simpler. That lowers cost of goods and makes it easier to roll out globally, especially in markets that cannot afford combination injectors.
Inside the 448-person Phase 2 trial
The diabetes study enrolled 448 adults with HbA1c around 7.8-8.0% despite metformin, with about 40% already taking an SGLT2 inhibitor. Participants either received once-weekly subcutaneous amycretin (0.4 mg up to 40 mg) or a once-daily oral capsule (6 mg up to 50 mg). Everyone titrated over several weeks to dodge GI blowback.
By week 36, the injectable cohort logged up to –1.8 percentage points in HbA1c from baseline while placebo barely moved (–0.2%). Nearly 89% of people on the higher weekly doses brought HbA1c under 7%, and 76% landed at or below 6.5%. The oral arm did not match that but still dropped HbA1c by as much as –1.5 points and got 78% under 7%.
Weight loss mirrored the glycemic wins:
- Weekly subcutaneous: up to –14.5% from a 99 kg baseline, versus –2.6% on placebo.
- Oral: up to –10.1% from a 101 kg baseline, versus –2.5% on placebo.
Novo noted that weight loss had not plateaued by week 36 on the highest injectable or oral doses, which means the curve could keep bending with longer exposure the same way Wegovy and tirzepatide curves flatten only after 60+ weeks.
Why the oral arm is a big deal
Oral incretins are still rare. Semaglutide’s oral form peaks around 3-4% weight loss in diabetes trials even with the 50 mg tablet now in late-stage testing. Amycretin’s pill already quadrupled that and stayed tolerable enough to keep most people on therapy. If Novo keeps the daily pill within 10-12% weight loss, there will finally be an oral option that legitimately competes with injectables.
The physiological trick is amylin signaling. When you stack amylin on GLP-1, you get tighter control of post-prandial glucose and a calmer hypothalamus. People feel full sooner with fewer GI fireworks because amylin slows gastric emptying in a smoother pattern than GLP-1 alone. That may be why the oral regimen avoids the jagged nausea curve seen with high-dose oral semaglutide.
Safety profile and tolerability
Side effects looked like every other incretin study: mostly mild to moderate nausea, vomiting, and diarrhea upfront. Novo did not report scary pancreatitis or thyroid cancer signals. Importantly, the share of patients dropping out because of tolerability was lower than in CagriSema studies, likely because you are not juggling two separate actives with their own titration quirks.
Investigators only kept people on the target maintenance dose for the final four weeks. That means we still need to see whether longer exposure to the highest 40 mg weekly or 50 mg oral doses introduces antibody formation, sustained GI issues, or rare adverse events. But nothing in the Phase 2 dataset suggests a hidden deal-breaker.
Strategic implications for Novo (and everyone else)
Before this readout, Novo telegraphed that amycretin was mostly an obesity play. After seeing the HbA1c and weight curves, leadership immediately approved Phase 3 diabetes trials starting this year. That is a direct response to Torezepatide eating the type 2 diabetes market. If amycretin can match Zepbound-like weight loss and beat it on convenience, Novo keeps its foot on the gas even while Wegovy supply stays tight.
There is also a scale advantage over CagriSema. Amycretin can live inside a single pen, single cartridge, and eventually a single oral blister pack. CagriSema still needs two active pharmaceutical ingredients, which complicates ramping up millions of doses. If amycretin can deliver the same metabolic outcomes with half the manufacturing complexity, Novo will push it hard.
Expect Phase 3 protocols to test amycretin in three buckets: general obesity, type 2 diabetes on oral meds, and combination therapy with basal insulin. Watch how Novo sequences these launches relative to Wegovy’s higher-dose programs and whether they reserve supply for countries that cannot get tirzepatide yet.
What this means if you are on existing GLP-1 therapy
If you already respond well to semaglutide or tirzepatide, amycretin is not a reason to jump ship today. It is a reason to keep an eye on access two years from now. The weekly shot could be a bridge between Zepbound’s potency and Wegovy’s safety profile. The oral capsule could finally make serious weight loss possible for people who hate needles or cannot refrigerate meds consistently.
The more immediate takeaway is confidence that dual-receptor designs are here to stay. Amycretin’s numbers confirm that adding amylin signaling to GLP-1 is not just incremental: it changes appetite, glucose, and weight curves enough to justify a whole new franchise. That also means insurers will soon have to write policies that account for injectables and pills delivering double-digit weight loss. The pricing fights will be fierce.
Takeaways
- Weekly amycretin cut HbA1c by up to 1.8 points and weight by 14.5% in 36 weeks, matching the metabolic impact of the CagriSema combo without needing two drugs.
- The daily oral amycretin arm still delivered 1.5-point HbA1c drops and 10.1% weight loss, signaling the first pill that can rival injectable incretins on body mass.
- Safety looked standard for incretins, with manageable GI symptoms and no surprise signals, though longer exposure will need to confirm durability.
- Novo is fast-tracking Phase 3 diabetes trials in 2026 because amycretin gives it a single-molecule answer to tirzepatide plus a serious oral option.
- Patients doing well on current GLP-1 therapy do not need to switch now, but amycretin could reshape access discussions once supply scales.
This is educational content, not medical advice. Talk to your doctor before starting any protocol.